- Report
- April 2025
- 200 Pages
Global
From €4074EUR$4,490USD£3,491GBP
- Report
- February 2025
- 218 Pages
Global
From €4355EUR$4,799USD£3,731GBP
- Report
- April 2025
- 200 Pages
Global
From €4074EUR$4,490USD£3,491GBP
- Report
- April 2025
- 200 Pages
Global
From €4074EUR$4,490USD£3,491GBP
- Report
- April 2025
- 200 Pages
Global
From €4074EUR$4,490USD£3,491GBP
- Report
- March 2025
- 200 Pages
Global
From €4074EUR$4,490USD£3,491GBP
- Report
- May 2024
- 140 Pages
Global
From €5897EUR$6,499USD£5,053GBP
- Report
- October 2024
- 200 Pages
Global
From €3403EUR$3,750USD£2,915GBP
- Report
- May 2021
- 50 Pages
China
From €2359EUR$2,600USD£2,021GBP
- Report
- February 2024
- 150 Pages
Global
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 80 Pages
Europe
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
North America
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
Germany
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
Italy
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
Oman
From €4310EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4310EUR$4,750USD£3,693GBP

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. It is a long-acting injectable medication that helps to reduce blood sugar levels by increasing insulin production and decreasing glucagon production. It also helps to reduce appetite and promote weight loss. Dulaglutide is approved by the US Food and Drug Administration (FDA) for use in adults with type 2 diabetes and is available in both brand and generic forms.
Dulaglutide is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions such as diabetes, obesity, thyroid disorders, and other endocrine and metabolic disorders. The market is expected to grow due to increasing prevalence of endocrine and metabolic disorders, rising awareness of the importance of early diagnosis and treatment, and the availability of new treatments.
Some companies in the Dulaglutide market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Show Less Read more